Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.
Identifieur interne : 000728 ( Main/Exploration ); précédent : 000727; suivant : 000729Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.
Auteurs : Kevin B. Ginsburg [États-Unis] ; Gregory B. Auffenberg [États-Unis] ; Ji Qi [États-Unis] ; Isaac J. Powell [États-Unis] ; Susan M. Linsell [États-Unis] ; James E. Montie [États-Unis] ; David C. Miller [États-Unis] ; Michael L. Cher [États-Unis]Source :
- European urology [ 1873-7560 ] ; 2018.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Afro-Américains (MeSH), Appréciation des risques (MeSH), Comorbidité (MeSH), Enregistrements (MeSH), Facteurs de risque (MeSH), Facteurs temps (MeSH), Humains (MeSH), Michigan (épidémiologie), Mâle (MeSH), Observation (surveillance clinique) (MeSH), Perdus de vue (MeSH), Population d'origine européenne (MeSH), Sujet âgé (MeSH), Surveillance de la population (MeSH), Tumeurs de la prostate (diagnostic), Tumeurs de la prostate (ethnologie), Tumeurs de la prostate (mortalité), Tumeurs de la prostate (thérapie), État de santé (MeSH), Évolution de la maladie (MeSH).
- MESH :
- diagnostic : Tumeurs de la prostate.
- ethnologie : Tumeurs de la prostate.
- mortalité : Tumeurs de la prostate.
- thérapie : Tumeurs de la prostate.
- épidémiologie : Michigan.
- Adulte d'âge moyen, Afro-Américains, Appréciation des risques, Comorbidité, Enregistrements, Facteurs de risque, Facteurs temps, Humains, Mâle, Observation (surveillance clinique), Perdus de vue, Population d'origine européenne, Sujet âgé, Surveillance de la population, État de santé, Évolution de la maladie.
English descriptors
- KwdEn :
- African Americans (MeSH), Aged (MeSH), Comorbidity (MeSH), Disease Progression (MeSH), European Continental Ancestry Group (MeSH), Health Status (MeSH), Humans (MeSH), Lost to Follow-Up (MeSH), Male (MeSH), Michigan (epidemiology), Middle Aged (MeSH), Population Surveillance (MeSH), Prostatic Neoplasms (diagnosis), Prostatic Neoplasms (ethnology), Prostatic Neoplasms (mortality), Prostatic Neoplasms (therapy), Registries (MeSH), Risk Assessment (MeSH), Risk Factors (MeSH), Time Factors (MeSH), Watchful Waiting (MeSH).
- MESH :
- geographic , epidemiology : Michigan.
- diagnosis : Prostatic Neoplasms.
- ethnology : Prostatic Neoplasms.
- mortality : Prostatic Neoplasms.
- therapy : Prostatic Neoplasms.
- African Americans, Aged, Comorbidity, Disease Progression, European Continental Ancestry Group, Health Status, Humans, Lost to Follow-Up, Male, Middle Aged, Population Surveillance, Registries, Risk Assessment, Risk Factors, Time Factors, Watchful Waiting.
Abstract
Active surveillance (AS) has emerged as the preferred management strategy for many men with prostate cancer (PC); however, insufficient longitudinal monitoring may increase the risk of poor outcomes. We sought to determine rates of patients becoming lost to follow-up (LTFU) and associated risk factors in a large AS cohort. The Michigan Urologic Surgery Improvement Collaborative (MUSIC) maintains a prospective registry of PC patients from 44 academic and community urology practices. Over a 6-yr period (2011-2017), we identified patients managed with AS. LTFU was defined as any 18-mo period where no pertinent surveillance testing was entered in the registry. With a median surveillance period of 32 mo, the estimated 2-yr LTFU-free probability calculated by Kaplan-Meier method was 90% (95% confidence interval [CI]=89-92%). Both African American race (hazard ratio [HR]: 2.77, 95% CI=1.81-4.24) and Charlson comorbidity index ≥1 (HR: 1.55, 95% CI=1.08-2.23) were independently associated with increased risk of LTFU. There was variability in rates of estimated 2-yr LTFU-free survival across MUSIC practices, ranging from 52% (95% CI=21-100%) to 99% (95% CI=97-100%), with a median of 96% (interquartile range: 94-98%), although this did not reach statistical significance (p=0.076). These data reveal opportunities for urology practices to identify systems to reduce rates of LTFU and improve the long-term safety of AS. PATIENT SUMMARY: With a median observation period of 32 mo, an estimated 10% of patients will be lost to follow-up at the 2 yr time point while on AS. African American men and generally unhealthy patients were at increased risk, and there was variability from one urology practice to another. There is ample opportunity to improve the quality of the performance of AS.
DOI: 10.1016/j.eururo.2018.08.010
PubMed: 30177290
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.</title><author><name sortKey="Ginsburg, Kevin B" sort="Ginsburg, Kevin B" uniqKey="Ginsburg K" first="Kevin B" last="Ginsburg">Kevin B. Ginsburg</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Wayne State University, School of Medicine, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Auffenberg, Gregory B" sort="Auffenberg, Gregory B" uniqKey="Auffenberg G" first="Gregory B" last="Auffenberg">Gregory B. Auffenberg</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA; Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA; Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Qi, Ji" sort="Qi, Ji" uniqKey="Qi J" first="Ji" last="Qi">Ji Qi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Powell, Isaac J" sort="Powell, Isaac J" uniqKey="Powell I" first="Isaac J" last="Powell">Isaac J. Powell</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Wayne State University, School of Medicine, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Linsell, Susan M" sort="Linsell, Susan M" uniqKey="Linsell S" first="Susan M" last="Linsell">Susan M. Linsell</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Montie, James E" sort="Montie, James E" uniqKey="Montie J" first="James E" last="Montie">James E. Montie</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Cher, Michael L" sort="Cher, Michael L" uniqKey="Cher M" first="Michael L" last="Cher">Michael L. Cher</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA. Electronic address: mcher@med.wayne.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Wayne State University, School of Medicine, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:30177290</idno><idno type="pmid">30177290</idno><idno type="doi">10.1016/j.eururo.2018.08.010</idno><idno type="wicri:Area/Main/Corpus">000710</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000710</idno><idno type="wicri:Area/Main/Curation">000710</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000710</idno><idno type="wicri:Area/Main/Exploration">000710</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.</title><author><name sortKey="Ginsburg, Kevin B" sort="Ginsburg, Kevin B" uniqKey="Ginsburg K" first="Kevin B" last="Ginsburg">Kevin B. Ginsburg</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Wayne State University, School of Medicine, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Auffenberg, Gregory B" sort="Auffenberg, Gregory B" uniqKey="Auffenberg G" first="Gregory B" last="Auffenberg">Gregory B. Auffenberg</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA; Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA; Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Qi, Ji" sort="Qi, Ji" uniqKey="Qi J" first="Ji" last="Qi">Ji Qi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Powell, Isaac J" sort="Powell, Isaac J" uniqKey="Powell I" first="Isaac J" last="Powell">Isaac J. Powell</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Wayne State University, School of Medicine, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Linsell, Susan M" sort="Linsell, Susan M" uniqKey="Linsell S" first="Susan M" last="Linsell">Susan M. Linsell</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Montie, James E" sort="Montie, James E" uniqKey="Montie J" first="James E" last="Montie">James E. Montie</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Cher, Michael L" sort="Cher, Michael L" uniqKey="Cher M" first="Michael L" last="Cher">Michael L. Cher</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA. Electronic address: mcher@med.wayne.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Wayne State University, School of Medicine, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><series><title level="j">European urology</title><idno type="eISSN">1873-7560</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>African Americans (MeSH)</term><term>Aged (MeSH)</term><term>Comorbidity (MeSH)</term><term>Disease Progression (MeSH)</term><term>European Continental Ancestry Group (MeSH)</term><term>Health Status (MeSH)</term><term>Humans (MeSH)</term><term>Lost to Follow-Up (MeSH)</term><term>Male (MeSH)</term><term>Michigan (epidemiology)</term><term>Middle Aged (MeSH)</term><term>Population Surveillance (MeSH)</term><term>Prostatic Neoplasms (diagnosis)</term><term>Prostatic Neoplasms (ethnology)</term><term>Prostatic Neoplasms (mortality)</term><term>Prostatic Neoplasms (therapy)</term><term>Registries (MeSH)</term><term>Risk Assessment (MeSH)</term><term>Risk Factors (MeSH)</term><term>Time Factors (MeSH)</term><term>Watchful Waiting (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Afro-Américains (MeSH)</term><term>Appréciation des risques (MeSH)</term><term>Comorbidité (MeSH)</term><term>Enregistrements (MeSH)</term><term>Facteurs de risque (MeSH)</term><term>Facteurs temps (MeSH)</term><term>Humains (MeSH)</term><term>Michigan (épidémiologie)</term><term>Mâle (MeSH)</term><term>Observation (surveillance clinique) (MeSH)</term><term>Perdus de vue (MeSH)</term><term>Population d'origine européenne (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Surveillance de la population (MeSH)</term><term>Tumeurs de la prostate (diagnostic)</term><term>Tumeurs de la prostate (ethnologie)</term><term>Tumeurs de la prostate (mortalité)</term><term>Tumeurs de la prostate (thérapie)</term><term>État de santé (MeSH)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Michigan</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="ethnologie" xml:lang="fr"><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="ethnology" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Michigan</term></keywords><keywords scheme="MESH" xml:lang="en"><term>African Americans</term><term>Aged</term><term>Comorbidity</term><term>Disease Progression</term><term>European Continental Ancestry Group</term><term>Health Status</term><term>Humans</term><term>Lost to Follow-Up</term><term>Male</term><term>Middle Aged</term><term>Population Surveillance</term><term>Registries</term><term>Risk Assessment</term><term>Risk Factors</term><term>Time Factors</term><term>Watchful Waiting</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Afro-Américains</term><term>Appréciation des risques</term><term>Comorbidité</term><term>Enregistrements</term><term>Facteurs de risque</term><term>Facteurs temps</term><term>Humains</term><term>Mâle</term><term>Observation (surveillance clinique)</term><term>Perdus de vue</term><term>Population d'origine européenne</term><term>Sujet âgé</term><term>Surveillance de la population</term><term>État de santé</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Active surveillance (AS) has emerged as the preferred management strategy for many men with prostate cancer (PC); however, insufficient longitudinal monitoring may increase the risk of poor outcomes. We sought to determine rates of patients becoming lost to follow-up (LTFU) and associated risk factors in a large AS cohort. The Michigan Urologic Surgery Improvement Collaborative (MUSIC) maintains a prospective registry of PC patients from 44 academic and community urology practices. Over a 6-yr period (2011-2017), we identified patients managed with AS. LTFU was defined as any 18-mo period where no pertinent surveillance testing was entered in the registry. With a median surveillance period of 32 mo, the estimated 2-yr LTFU-free probability calculated by Kaplan-Meier method was 90% (95% confidence interval [CI]=89-92%). Both African American race (hazard ratio [HR]: 2.77, 95% CI=1.81-4.24) and Charlson comorbidity index ≥1 (HR: 1.55, 95% CI=1.08-2.23) were independently associated with increased risk of LTFU. There was variability in rates of estimated 2-yr LTFU-free survival across MUSIC practices, ranging from 52% (95% CI=21-100%) to 99% (95% CI=97-100%), with a median of 96% (interquartile range: 94-98%), although this did not reach statistical significance (p=0.076). These data reveal opportunities for urology practices to identify systems to reduce rates of LTFU and improve the long-term safety of AS. PATIENT SUMMARY: With a median observation period of 32 mo, an estimated 10% of patients will be lost to follow-up at the 2 yr time point while on AS. African American men and generally unhealthy patients were at increased risk, and there was variability from one urology practice to another. There is ample opportunity to improve the quality of the performance of AS.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30177290</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>12</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur Urol</ISOAbbreviation></Journal><ArticleTitle>Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.</ArticleTitle><Pagination><MedlinePgn>704-707</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0302-2838(18)30595-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2018.08.010</ELocationID><Abstract><AbstractText>Active surveillance (AS) has emerged as the preferred management strategy for many men with prostate cancer (PC); however, insufficient longitudinal monitoring may increase the risk of poor outcomes. We sought to determine rates of patients becoming lost to follow-up (LTFU) and associated risk factors in a large AS cohort. The Michigan Urologic Surgery Improvement Collaborative (MUSIC) maintains a prospective registry of PC patients from 44 academic and community urology practices. Over a 6-yr period (2011-2017), we identified patients managed with AS. LTFU was defined as any 18-mo period where no pertinent surveillance testing was entered in the registry. With a median surveillance period of 32 mo, the estimated 2-yr LTFU-free probability calculated by Kaplan-Meier method was 90% (95% confidence interval [CI]=89-92%). Both African American race (hazard ratio [HR]: 2.77, 95% CI=1.81-4.24) and Charlson comorbidity index ≥1 (HR: 1.55, 95% CI=1.08-2.23) were independently associated with increased risk of LTFU. There was variability in rates of estimated 2-yr LTFU-free survival across MUSIC practices, ranging from 52% (95% CI=21-100%) to 99% (95% CI=97-100%), with a median of 96% (interquartile range: 94-98%), although this did not reach statistical significance (p=0.076). These data reveal opportunities for urology practices to identify systems to reduce rates of LTFU and improve the long-term safety of AS. PATIENT SUMMARY: With a median observation period of 32 mo, an estimated 10% of patients will be lost to follow-up at the 2 yr time point while on AS. African American men and generally unhealthy patients were at increased risk, and there was variability from one urology practice to another. There is ample opportunity to improve the quality of the performance of AS.</AbstractText><CopyrightInformation>Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ginsburg</LastName><ForeName>Kevin B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auffenberg</LastName><ForeName>Gregory B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA; Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Isaac J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linsell</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montie</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, School of Medicine, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cher</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Urology, Wayne State University, School of Medicine, Detroit, MI, USA. Electronic address: mcher@med.wayne.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2018 Dec;74(6):708-709</RefSource><PMID Version="1">30224197</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">African Americans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059012" MajorTopicYN="Y">Lost to Follow-Up</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008824" MajorTopicYN="N" Type="Geographic">Michigan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057832" MajorTopicYN="Y">Watchful Waiting</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Active surveillance</Keyword><Keyword MajorTopicYN="Y">Prostate cancer</Keyword><Keyword MajorTopicYN="Y">Quality improvement</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>02</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30177290</ArticleId><ArticleId IdType="pii">S0302-2838(18)30595-5</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2018.08.010</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Ginsburg, Kevin B" sort="Ginsburg, Kevin B" uniqKey="Ginsburg K" first="Kevin B" last="Ginsburg">Kevin B. Ginsburg</name></region><name sortKey="Auffenberg, Gregory B" sort="Auffenberg, Gregory B" uniqKey="Auffenberg G" first="Gregory B" last="Auffenberg">Gregory B. Auffenberg</name><name sortKey="Cher, Michael L" sort="Cher, Michael L" uniqKey="Cher M" first="Michael L" last="Cher">Michael L. Cher</name><name sortKey="Linsell, Susan M" sort="Linsell, Susan M" uniqKey="Linsell S" first="Susan M" last="Linsell">Susan M. Linsell</name><name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name><name sortKey="Montie, James E" sort="Montie, James E" uniqKey="Montie J" first="James E" last="Montie">James E. Montie</name><name sortKey="Powell, Isaac J" sort="Powell, Isaac J" uniqKey="Powell I" first="Isaac J" last="Powell">Isaac J. Powell</name><name sortKey="Qi, Ji" sort="Qi, Ji" uniqKey="Qi J" first="Ji" last="Qi">Ji Qi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteMusiqueV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000728 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000728 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SanteMusiqueV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30177290
|texte= Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30177290" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SanteMusiqueV1
| This area was generated with Dilib version V0.6.38. |  |